Cancer stem cells (CSCs) represent a formidable challenge in oncology due to their unique ability to self-renew, differentiate, and fuel tumor initiation, progression, metastasis, and therapy resistance. Despite decades of research, the intricate molecular mechanisms that govern the behavior of CSCs remain incompletely understood. Recently, non-coding RNAs, particularly long non-coding RNAs (lncRNAs), have emerged as pivotal regulators orchestrating CSC biology, opening new avenues in cancer research and therapeutic development.
Among lncRNAs, pseudogene-derived transcripts are gaining particular interest. Historically regarded as non-functional “genomic relics,” pseudogene-derived lncRNAs are now recognized as structurally and functionally active molecules that closely parallel their conventional lncRNA counterparts. A comprehensive review spearheaded by researchers affiliated with prominent Iranian medical universities meticulously elucidates how these pseudogene-derived lncRNAs influence CSC dynamics by modulating intricate regulatory networks involving microRNAs, protein interactions, and key signaling cascades.
Central to their function, pseudogene-derived lncRNAs predominantly act as competitive endogenous RNAs (ceRNAs). This mechanism entails the “sponging” of microRNAs (miRNAs), effectively sequestering these small regulatory RNAs and preventing them from binding to their target messenger RNAs. By intercepting miRNAs, these lncRNAs relieve repression on critical gene targets, thereby modulating gene expression post-transcriptionally and fine-tuning cellular phenotypes essential for maintaining the stemness of cancer cells.
The review highlights how pseudogene-derived lncRNAs hijack multiple oncogenic signaling pathways that are paramount for CSC maintenance and malignant behavior. Among these pathways are Wnt/β-catenin, PI3K/AKT, TGF-β, ERK, and JAK-STAT. Each of these pathways governs essential aspects of CSC physiology including proliferation, survival, differentiation blockade, and therapeutic resistance. Intriguingly, these lncRNAs can exert either tumor-promoting or tumor-suppressive effects, a duality that underscores the complexity of their regulatory roles within the cancer stem cell niche.
Crucial examples underscore the biological and clinical significance of these molecules. CYP4Z2P, a pseudogene-derived lncRNA, has been implicated in augmenting CSC properties and chemoresistance in breast cancer, positioning it as a potential driver of therapeutic failure. Similarly, RPSAP52 enhances glioblastoma stemness by engaging in ceRNA networks that elevate oncogenic signaling. The RSU1P2/let-7a/Tex10 axis exemplifies a sophisticated regulatory circuit in liver cancer where pseudogene-derived lncRNAs activate the Wnt/β-catenin pathway, reinforcing CSC-associated gene signatures.
Moreover, pseudogene-derived lncRNAs also engage in direct protein interactions that stabilize stemness factors. For instance, PDIA3P1 in esophageal squamous cell carcinoma interacts with the OCT4 transcription factor, shielding it from proteasomal degradation and establishing a positive feedback loop that perpetuates stem cell-like states, tumor aggressiveness, and possibly therapy resistance. Such interactions highlight an additional layer of regulatory complexity extending beyond ceRNA activity.
On the other hand, certain pseudogene-derived lncRNAs exhibit tumor-suppressive functions by diminishing cancer stemness. The lncRNAs TPTEP1, GUSBP11, and AZGP1P2 have been shown to downregulate CSC traits in glioma, triple-negative breast cancer, and prostate cancer, respectively. This evidence reflects the context-dependent effects of these molecules and suggests potential therapeutic applications aiming to restore their expression or mimic their function to inhibit CSC-driven tumor propagation.
Apart from their mechanistic roles, the aberrant expression levels of these pseudogene-derived lncRNAs correlate strongly with tumor grade, metastatic potential, and patient prognosis. This correlation underscores their promise as robust diagnostic and prognostic biomarkers in a range of malignancies. Non-invasive assays detecting circulating lncRNAs or in situ hybridization in biopsy specimens could enhance personalized cancer management by delineating high-risk patients and monitoring treatment response.
To unravel the multifaceted roles of these lncRNAs, researchers deploy a comprehensive experimental pipeline beginning with high-throughput RNA sequencing and sophisticated bioinformatics analyses. Validation steps involve quantitative techniques such as RT-qPCR and fluorescent in situ hybridization (FISH). Functional interrogation is performed using molecular tools like CRISPR/Cas9 genome editing and siRNA-mediated knockdown to elucidate their effects on CSC properties in vitro and in vivo.
Further insights into molecular interactions are garnered through biochemical assays including RNA immunoprecipitation (RIP), which identifies lncRNA-protein complexes, and dual-luciferase reporter assays that confirm miRNA sponging activities. These approaches collectively illuminate the ceRNA networks and protein partnerships driving the stemness-promoting or suppressive functions of pseudogene-derived lncRNAs, elucidating novel regulatory circuits exploitable for therapeutic targeting.
This review harmonizes disparate studies into a cohesive narrative emphasizing the biogenesis, functional mechanisms, and clinical implications of pseudogene-derived lncRNAs within CSC biology. The authors convincingly outline how these non-coding regulators are integral components of the cancer epigenome, modulating signals that determine tumor aggressiveness, resistance, and relapse, thereby offering exciting prospects for novel anti-cancer strategies.
Looking forward, the translational potential of targeting pseudogene-derived lncRNAs remains immense. Therapeutic interventions could focus on disrupting oncogenic lncRNA-miRNA interactions, stabilizing tumor-suppressive lncRNAs, or leveraging their biomarker potential for patient stratification. Such modalities may complement existing chemotherapies and immunotherapies, heralding a new era in precision oncology where non-coding RNA therapeutics specifically eradicate CSC populations and improve patient outcomes.
In summary, this seminal review advances our understanding of cancer stem cell regulation by highlighting the emerging roles of pseudogene-derived lncRNAs. These molecules represent a previously underappreciated layer of genetic regulation with profound effects on tumor biology, underscoring the necessity to integrate non-coding RNA research into mainstream cancer therapeutics and diagnostics.
Subject of Research: Pseudogene-derived long non-coding RNAs (lncRNAs) and their regulatory roles in cancer stem cells.
Article Title: Emerging roles of pseudogene-derived lncRNAs in cancer stem cells: Non-coding clues and therapeutic targets in cancer medicine
News Publication Date: Information not provided.
Web References: Information not provided.
References: Information not provided.
Image Credits: Seyed Taha Nourbakhsh, Fatemeh Mohamadhashem, Elahe Soltani Fard, Faezeh Mohamadhashem, Abdolreza Daraei
Keywords: Cancer stem cells, pseudogene-derived lncRNAs, ceRNA, miRNA sponging, Wnt/β-catenin, PI3K/AKT, TGF-β, ERK, JAK-STAT, OCT4, chemoresistance, tumor biomarkers
